<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220812055665N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-28</date_registration>
      <primary_sponsor>Gorgan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of oral melatonin in reduction pain during venipuncture _a double blind clinical trial</public_title>
      <acronym></acronym>
      <scientific_title>The effect of oral melatonin in reduction pain during venipuncture _a double blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>202</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66025</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method and tool: In this study, we will use the restricted randomization method of the block randomization type. Blocking is usually used in order to create a balance in the number of samples allocated to each of the studied groups. This feature helps researchers to ensure that the number of samples allocated to each of the study groups is equal in cases where intermediate analyzes are needed during the sampling process. The total size of the blocks is equal and in this trial we will have two groups of 6 blocks including 3 participants in the intervention group and 3 participants in the control group. The randomization tool is also used from random allocation software, which, in addition to simple randomization, is capable of generating random sequences using the block method, Blinding description: Concealment: We will use allocation concealment. By using opaque letter envelopes sealed with a random sequence, in this method, each of the generated random sequences is recorded on a card and the cards are placed inside the letter envelopes in order. In order to maintain a random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lid of the letter envelopes is glued and placed in a box. At the time of starting the registration of participants, based on the order in which eligible participants entered the study, one of the envelopes will be opened and the assigned group of that participant will be revealed.
Double masked blind
Both patients and all researchers related to patients are unaware of the patient's perceived exposure. The patient can be identified with a code that is placed in an envelope, and in another place it is clear whether this number is a medicine or a placebo.</study_design>
      <phase>3</phase>
      <hc_freetext>Pain during venipuncture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  This group includes children to reduce pain and restlessness during venipuncture, melatonin drug will be used for them before venipuncture, and then the success of this method will be evaluated. This group includes 3 to 6 year old children receiving melatonin medication, who receive a single dose of 0.5 mg/kg and a maximum dose of 5 mg 30 to 60 minutes before venipuncture. The melatonin tablet is from jalinous company and has a dose of 5 mg, which is dissolved in 5 cc of water by a trained nurse before use and is given to the child with the mentioned dose. Older children can take the medicine in pill form. After 30 to 60 minutes, venipuncture will be done, and during venipuncture, the child's reactions will be evaluated based on the flacc criteria. Intervention 2: Control group: This group includes children to reduce pain and restlessness during venipuncture, melatonin placebo will be used for them before venipuncture, and then the success of this method will be evaluated. This group includes children aged 3 to 6 years who receive a single dose of placebo with a dose of 0.5 mg/kg and a maximum dose of 5 mg 30 to 60 minutes before venipuncture. The melatonin placebo is from jalinuos company and is completely similar to the 5 mg melatonin tablet. The placebo is dissolved in 5 cc of water by a trained nurse and given to the child with the mentioned dose. Older children can take the medicine in the form of tablets with the correct dosage. After 30 to 60 minutes, venipuncture will be done, and during venipuncture, the child's reactions will be evaluated based on the flacc criteria.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is preservation of personal information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zohre Akbari jokar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>15 Golara, 8 golshahr, golshahr blvd, gorgan</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4916984654</zip>
        <telephone>+98 17 3252 2711</telephone>
        <email>Zohreakbari2351@yahoo.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zohre Akbari Jokar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>15 Golara, 8 golshahr, golshahr blvd, gorgan</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4916984654</zip>
        <telephone>+98 17 3252 0369</telephone>
        <email>zohreakbari2351@yahoo.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>children with 3-6 y reffered to Taleghani Hospital
Parental consent for the child to participate in the study
need to venipuncture for intravenous infusion</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>loss of consciousness
acute and life threatening state
any psychological disorder (  autism , ADHD)
any reaction to melatonin
use any sedative or pain relief  drug
emergency state</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  This group includes children to reduce pain and restlessness during venipuncture, melatonin drug will be used for them before venipuncture, and then the success of this method will be evaluated. This group includes 3 to 6 year old children receiving melatonin medication, who receive a single dose of 0.5 mg/kg and a maximum dose of 5 mg 30 to 60 minutes before venipuncture. The melatonin tablet is from jalinous company and has a dose of 5 mg, which is dissolved in 5 cc of water by a trained nurse before use and is given to the child with the mentioned dose. Older children can take the medicine in pill form. After 30 to 60 minutes, venipuncture will be done, and during venipuncture, the child's reactions will be evaluated based on the flacc criteria.</i_keyword>
      <i_keyword>Control group: This group includes children to reduce pain and restlessness during venipuncture, melatonin placebo will be used for them before venipuncture, and then the success of this method will be evaluated. This group includes children aged 3 to 6 years who receive a single dose of placebo with a dose of 0.5 mg/kg and a maximum dose of 5 mg 30 to 60 minutes before venipuncture. The melatonin placebo is from jalinuos company and is completely similar to the 5 mg melatonin tablet. The placebo is dissolved in 5 cc of water by a trained nurse and given to the child with the mentioned dose. Older children can take the medicine in the form of tablets with the correct dosage. After 30 to 60 minutes, venipuncture will be done, and during venipuncture, the child's reactions will be evaluated based on the flacc criteria.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score is primary outcome. Timepoint: 30  to 60 min after drug consumption. Method of measurement: FLACC score  (  measurement changes of face,legs,activity,cry,consolability).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Secondary outcome is anxiety. Timepoint: 30-60 min after drug consumption. Method of measurement: observation.</sec_outcome>
      <sec_outcome>Success in venipuncture. Timepoint: 30-60 min after drug consumption. Method of measurement: observation.</sec_outcome>
      <sec_outcome>Child cooperation. Timepoint: 30-60 min after drug consumption. Method of measurement: observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gorgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-16</approval_date>
        <contact_name>Ethics committee of Golestan University of medical science</contact_name>
        <contact_address>Hirkan Blvd Gorgan Golestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
